643-12-9 (D-手性肌醇,D-chiro Inositol)

D-手性肌醇;1D-chiro-Inositol 1D-手性肌醇;1D-手性肌醇;D-(+)-手性肌醇;D-(+)-手性-肌醇;D-肌醇;荞麦种子提取物(DCI);1D-手性纤维醇;3,5,6-六羟基环己烷;1,2,4/3,5,6-六羟基环己烷;手性肌醇;

D-chiro-Inositol;D-chiro Inositol;D-(+)-chiro-Inositol;1,2,4;1D-chiro-Inositol;3,5,6-hexahydroxycyclohexane;cis-inositol;cyclohexanehexol;D-Chiro-inositol(DCI);D-CHIRO-INOSITOL(DISD);D-Inositol;Scyllo-inositol;myo-inositol;inositol;Muco-Inositol;i-Inositol;epi-Inositol;Allo-inositol;meso-Inositol;1L-Chiro-inositol;Myoinositol;Scyllitol;mesoinositol;Quercinitol;Myoinosite;Dambose;Cyclohexane-1,2,3,4,5,6-hexaol;Neo-inositol;Meat sugar;Cocositol;Inositene;Phaseomannite;Inositina;Inosital;cyclohexane-1,2,3,4,5,6-hexol;Iso-inositol;Phaseomannitol;Cyclohexitol;Scyllite;Mesoinosite;Mesoino;HMS2235H05;I0628;488-58-4;41546-34-3;Q2974313;CHEBI:23927;NCI60_041778;DTXSID30110000;CHEBI:27372;Mesoinosit;SMR000857145;NCGC00159409-04;MFCD00065455;Q3347078;STL453612;Z1486007281;NSC127230;neoinositol;63GQX5QW03;rel-(1r,2r,3r,4r,5r,6r)-Cyclohexane-1,2,3,4,5,6-hexaol;scyllo-Inositol, >=98%;SCHEMBL12735687;(1R,2R,3S,4S,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol;1,3,4,5,6-Cyclohexanehexol;CDAISMWEOUEBRE-GNIYUCBRSA-N;(-)-Inositol;I0632;KBioSS_002075;HMS2091N13;rac-chiro-1,2,3,4,5,6-cyclohexanehexol;CS-0083766;AKOS006332036;W-202862;EN300-25914216;(1R,2R,3S,4R,5r,6S)-cyclohexane-1,2,3,4,5,6-hexaol;EN300-658805;HY-W010041;AKOS015960633;NSC-757076;MI;DTXSID7023146;E78671;Inositol, allo-;DTXSID601028825;C06151;Inositol [USAN:NF];L-(-)-chiro-Inositol;Spectrum_001595;NSC55558;bmse000102;(1R,2S,3s,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexol;D91187;Q3011024;J101.891D;DTXSID50905091;CHEBI:22357;AI3-16111;643-12-9;Inositol, scyllo-;rac-chiro-inositol;576-63-6;epi-Inositol, >=98.0% (HPLC);NSC25142;Spectrum5_000961;EINECS 207-682-0;643-10-7;I0633;SY060836;CHEBI:17268;1,2,3,4,5,6-Cyclohexanehexol #;NSC55552;GTPL4649;AKOS006240678;NSC55551;DTXCID2065254;C06152;CDAISMWEOUEBRE-GPIVLXJGSA-N;AKOS015994742;EPIINOSITOL;SCHEMBL187397;NSC8101;(1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol;UNII-R1Y9F3N15A;(1R,2R,3S,4S,5S,6R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL;(1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexol;MFCD00272608;myo-Inositol, purum, >=98.0% (HPLC);(1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexaol;CHEBI:10642;R1Y9F3N15A;KBio2_004643;INOSITOL [MART.];chiro-inositol;Mesovit;C06153;488-59-5;EINECS 201-781-2;CHEMBL1231671;NSC-25142;SCHEMBL4748543;Matezodambose;Inosital (TN);AS-68396;NCGC00159409-02;Inositol (NF);SCHEMBL13058696;D-chiro-Inositol, >=98.0% (HPLC);CS-0369552;NSC-55552;Inositol, United States Pharmacopeia (USP) Reference Standard;J9.771C;NSC 127230;INOSITOL [WHO-DD];(+)-Epi-Inositol;1,2,3/4,5,6-cyclohexanehexol;SCHEMBL5969;s4530;S6176;NSC-45517;myo-Inositol, SAJ special grade, >=99.0%;AKOS027327401;myo-Inositol, >=99%;DB15350;Inositol, meso-;CHEBI:27374;BRD-K52618540-001-09-9;SCHEMBL13207905;NS00007581;CHEBI:23311;(1R,2R,3R,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol;GTPL4645;I0040;cis-1,2,4-trans-3,5,6-Cyclohexanehexol;CHEBI:25492;UNII-587A93P465;NSC45517;MEGxp0_001817;INOSITOL (D);CAS-87-89-8;Inositol, myo- (8CI);KBio2_007211;ELND005;1,2,3,4,5,6-Hexahydroxycyclohexane;INS;inositol myo-;Spectrum3_001053;epi-Inositol; Inositol, epi- (8CI); epi-Cyclohexanehexol;myo-Inositol, Vetec(TM) reagent grade, 99%;CHEMBL468154;1,3,5/2,4,6-cyclohexanehexol;INOSITOL, MESO;HY-121962;1,2,4,5/3,6-cyclohexanehexol;(1R,2S,3r,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexol;HY-W016509;KBioGR_001885;SMR000857319;(1r,2R,3S,4r,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol;Q3023527;1VS4X81277;AZD-103;MLS001335968;EN300-82941;SCHEMBL13580047;C19891;488-54-0;UNII-9O6Y5O4P9W;SCHEMBL188237;ELND-005;GTPL4495;KS-1420;DTXSID101028820;MFCD01321249;GTPL4648;1D-myo-Inositol;1,2,3,5/4,6-Cyclohexanehexol;551-72-4;CHIRO-INOSITOLS;EINECS 207-681-5;(1R,2R,3R,4S,5S,6s)-cyclohexane-1,2,3,4,5,6-hexaol;cyclohexane-1R,2R,3S,4S,5R,6S-hexol;NS00074234;CHEMBL1950780;Inositol, chiro-;1,2,4/3,5,6-cyclohexanehexol;D91189;rel-(1R,2r,3S,4R,5s,6S)-Cyclohexane-1,2,3,4,5,6-hexaol;SCHEMBL13114116;SCHEMBL12377889;Inositol, neo-;Mesol;SCHEMBL6378921;allo-Inositol, 97%;CS-0185922;Mouse antialopecia factor;NSC-404118;CDAISMWEOUEBRE-OQYPVSDDSA-N;NS00079417;DTXSID901028824;NCGC00255362-01;NS00080101;SCHEMBL13114115;EN300-7361851;(1r,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol;Q2838375;SMR000857320;NSC 55558;NSC-55551;1,3,5/2,4,6-Hexahydroxycyclohexane;UNII-4661D3JP8D;UNII-8LQ63P85IC;W-202861;KBio3_001826;J101.889B;NSC 25142;LS-13189;inositols;Inositol, Pharmaceutical Secondary Standard; Certified Reference Material;SB46764;BSPBio_002606;L-chiro-Inositol;myo-Inositol, European Pharmacopoeia (EP) Reference Standard;AC-11070;HY-W127726;Inositol, muco-;NSC-103959;D91188;HMS2235M23;SCHEMBL187278;DB03106;Nucite;INOSITOL [INN];bmse000103;NSC 55552;D-CHIRO-INOSITOL [USP-RS];NCGC00159409-07;1D7A27BF-6060-4FA9-AC46-3BD18DBA406E;NCGC00178580-01;Q3331426;CCG-36096;NSC-8101;Pharmakon1600-01500352;myo-Inositol, p.a., 98.0%;EN300-19631206;C00137;I0631;(-)-chiro-Inositol;AKOS015912905;(+)-Chiro-Inositol;INOSITOL [FCC];Chiro-inositol, (+)-;L-Inositol;Chiro-inositol, (-)-;A836375;L-(-)-chiro-Inositol, 95%;UNII-6R79WV4R10;6R79WV4R10;myo-Inositol, for microbiology, >=99.0%;SCHEMBL6791918;CHEMBL1222251;cis-1,2,3,5-trans-4,6-Cyclohexanehexol;CS-W017225;Inositol, cis-;DB-051584;CCRIS 6745;W-203168;EN300-7411506;Rat antispectacled eye factor;(1s,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol;CHEMBL278373;UNII-4L6452S749;rel-(1S,2s,3s,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexaol;I0629;6917-35-7;1,3,5/4,6-Cyclohexanehexol;SCHEMBL959405;D-(+)-chiro-Inositol, 95%;INOSITOL [MI];KS-1284;SR-05000001655-1;L-myo-Inositol;epi-Cyclohexanehexol;INOSITOL [USAN];NS00079658;HMS3369B06;220128F1-89BF-442D-AD6D-E6D1EA7BA625;EINECS 209-000-7;INOSITOL [VANDF];AZD 103;W-203392;T72516;EN300-19632288;UNII-M94176HJ2F;Inositol (VAN);CDAISMWEOUEBRE-LOLGQZEGSA-N;myo-Inositol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture;DB13178;Inositol, myo-;(1R,2R,3R,4R,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol;AKOS015912934;CS-W010757;HY-B1411;Tox21_111642;MLS001335966;SCHEMBL188106;I-6500;DTXSID201028823;CHEMBL3976780;Inositol (VAN8C;DL-CHIRO-INOSITOL;Epitope ID:144993;CHEBI:27987;(1R,2R,3S,4S,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol;NSC-55558;Hexahydroxycyclohexane;NCGC00159409-08;1,2,3,4,5,6-cyclohexanehexol, (1alpha,2alpha,3alpha,4beta,5alpha,6beta);1,2,3,4,5,6-Cyclohexanehexol;Inositol, D-chiro-;cis-Inositol, >=98.0% (TLC);NS00080335;KBio2_002075;SB45039;Inositol, epi-;SCHEMBL14542470;SR-05000001655-5;HMS3373E05;AKOS027320475;EINECS 230-024-9;(1R,2S,3r,4R,5S,6r)-cyclohexane-1,2,3,4,5,6-hexol;F19572;CS-4782;MLS001335965;alloinositol;NSC 103959;(1s,2s,3s,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol;NSC103959;SCHEMBL187796;cis-1,3,5-trans-4,6-Cyclohexanehexol;HMS3369F20;SR-05000001655;8LQ63P85IC;MLS001332378;AKOS015960429;MFCD00799555;EINECS 211-393-5;SCHEMBL1055883;AKOS015895894;MFCD00003863;Bios I;DB-054642;MLS001332377;NCIOpen2_008191;J101.888D;Tox21_302035;EINECS 211-394-0;SCHEMBL5832;SCHEMBL5831;MLS001335967;D-(+)-Chiro Inositol;D-myo-Inositol;Inositol, i-;BCP25172;myo-Inositol, BioUltra, >=99.5% (HPLC);HMS2230N03;1.ALPHA.,2.ALPHA.,3.BETA.,4.ALPHA.,5.BETA.,6.BETA.-CYCLOHEXANEHEXOL;NS00080052;CS-0039882;1,2,3,4,5/6-cyclohexanehexol;Spectrum4_001193;W-203081;SBI-0051369.P003;Levoinositol;bmse000922;CS-0023004;NSC 404118;MYO-INOSITOL [EP MONOGRAPH];D-CHIRO-INOSITOL [WHO-DD];MFCD00077932;J101.892B;488-55-1;UNII-1VS4X81277;38876-99-2;2os9;(1r,2R,3S,4s,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol;ELND 005;D08079;1,2,4/3,5,6-Cyclohexane-1,2,3,4,5,6-hexol;9O6Y5O4P9W;cis-1,2,3,4,5,6-cyclohexanehexol;SB46855;(1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexaol;SCHEMBL959404;orthorhombic myo-inositol;Insitolum;SCHEMBL12711208;CDAISMWEOUEBRE-NIPYSYMMSA-N;DTXSID301028826;7B0CEF84-D9CE-4A88-AA7D-EC50C89387A5;NSC-127230;SCHEMBL12411898;Inositol, myo;DB-051583;1-L-chiro-Inositol;AS-68424;Q3205874;NCGC00178580-03;Q3589114;4irx;SB44732;bmse000901;NCGC00169828-01;SCHEMBL491333;1,2,3,4,5,6-HEXAHYDROXY-CYCLOHEXANE;AKOS024318869;myo-Inositol;meso-Inositol;NSC757076;4661D3JP8D;CHEBI:24848;DTXSID101028818;INOSITOL [USP-RS];HY-W021265;I0630;87-89-8;1L-myo-Inositol;587A93P465;HY-N3021;SCHEMBL6468882;scyllo-Cyclohexanehexol;CBU;Inosite;SCHEMBL12371461;Q407997;INOSITOL (L);1,2,3,4/5,6-cyclohexanehexol;1,2,3,5-trans-4,6-Cyclohexanehexol, cis-;4L6452S749;J101.890F;1,2,3,4,5,6-Cyclohexanehexol, (cis,cis,cis,trans,cis,trans)- #;bmse000113;2H3;Muscle sugar;NCGC00159409-03;Isoinositol;NSC404118;ACon1_002457;AS-10616;SCHEMBL21388397;UNII-63GQX5QW03;Inositol [Nonspecific isomer];M94176HJ2F;Q743661;Q-201583;SCHEMBL13114128;NSC 8101;M01914;1,2,3,4,5,6/0-cyclohexanetetrol;an inositol;Tox21_111642_1;AB00051982_13;D78450;(+)-Inositol;

MFCD00272608

CDAISMWEOUEBRE-UHFFFAOYSA-N

1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H

O([H])C1([H])C([H])(C([H])(C([H])(C([H])(C1([H])O[H])O[H])O[H])O[H])O[H]

211-394-0

29061390

肌醇及其磷酸盐已经被用于开发代谢稳定的胰岛素介质、抑制剂以及重要代谢功能（如糖酵解）的调节剂。因为缺乏水解不稳定的配糖键，所以肌醇在体内对降解酶很稳定。

由菲汀经水解、中和而得。将菲汀和水投入高压水解锅内，密闭加热，内压逐渐升至约0.5MPa，搅拌反应8h。检查物料pH值，2.5-3.0为反应终点。将水解液放入中和锅，用石灰乳中和，温度保持在70-80℃，pH值控制在7-8。用离心机甩出滤液，滤渣可作用肥料用（为磷酸钙）。将上述中和滤液加热至80-90℃，投入0.5-0.7%活性炭，并不断搅拌，约20min用砂蕊捧进行抽滤，滤出的清液吸入浓缩锅，在90℃浓缩4-5h，当相对密度达1.24-1.28时即可出料，放入搪瓷桶或不锈钢桶冷却。待有结晶析出时，用人工搅拌，冷至20-25℃，送入离心机甩干，即得黄色肌醇粗品，甩出粗母液可再次浓缩结晶。将水或线液加入粗品中，加热溶解，加入活性炭脱色，再加入氧氧化钡溶液和草酸铵溶液，分别沉淀除去硫酸根和钙离子。趁热过滤，滤液冷至30℃，结晶，过滤（母液套用），滤饼用少量乙醇洗涤，在80℃干燥6h，最后过18目筛，得肌醇。(1)将1份糠粕和10份水投入浸泡池，用盐酸或硫酸调PH至2.5-3.0，在室温下浸泡4-8h（冬季长，夏季短），糠粕中不溶性的植酸钙镁钾复盐转化为可溶性植酸钙镁钾式盐。过滤，并用水洗涤滤渣，滤渣可作饲料，合并滤液和洗液，用压缩空气搅拌，加入新鲜的石灰乳中和至PH6.8左右。中和液静置2h，使植酸钙充分沉淀，吸去上层清液，加入清水反复洗涤至洗涤液不呈淡黄色（中性）为止，下层白浆用压滤机压滤得膏状植酸钙即菲汀。将膏状菲汀和水投入高压水解反应锅混合打浆，浓度控制在25%，加热至内压0.5Mpa,搅拌反应8h,反应终点PH为2.5-3.0。水解液放入中和锅，在70-80℃下用石灰乳中和值PH7-8。过滤去渣，滤渣可做肥料。加入催化剂可以降低反应温度，缩短反应时间。水解液加热至80-90℃，加入0.5%-0.7%的活性炭，脱色后过滤，在90℃下将滤液浓缩4-5h，至相对密度1.24-1.28时出料。冷却至20-25℃结晶，分离得黄色肌醇粗品，滤液在进行浓缩结晶。粗品加热溶解于水，加活性炭脱色，加入氢氧化钡溶液和草酸铵溶液，沉淀除去硫酸根和钙离子。趁热过滤，滤液冷却至30℃，在结晶、分离，并用少量的乙醇洗涤。最后在80℃下干燥8h得成品。(2)以麸皮为原料，在30℃时用1%-1.5%的盐酸浸泡麸皮4-8h，经板框压滤机过滤，滤渣经2次浸泡，滤液用石灰乳中和值PH=7，充分搅拌10min，过滤、洗涤得植酸钙粗品。将粗品溶解于PH=1-2的盐酸溶液中，加入活性炭脱色过滤，滤液用10%的Na2CO3溶液调PH=4.5，搅拌10min,静置1-1.5h。弃上层清液，将植酸钙浆状液置于压力锅中，后续工艺同上。将1份糠粕和10份水投入浸泡池，用盐酸或硫酸调pH值至2.5～3.0，在室温下浸泡4～8h(冬季长夏季短)，糠粕中不溶性的植酸钙镁钾复盐转化为可溶性植酸钙镁酸式盐；过滤，并用水洗涤滤渣，滤渣可作饲料，合并滤液和洗液，用压缩空气搅拌，加入新鲜的石灰乳中和至pH值6.8左右；中和液静置2h，使植酸钙充分沉淀，吸去上层清液，加入清水反复洗涤至洗涤液不呈淡黄色(中性)为止；下层白浆用压滤机压滤得膏状植酸钙即菲汀。将膏状菲汀和水投入高压水解反应锅混合打浆，浓度控制在25%，加热至内压0.5MPa搅拌反应8h，反应终点pH值为2.5～3.0；水解液放人中和锅，在70~80℃下用石灰乳中和至pH值7～8；过滤去渣，滤渣可作肥料；加入催化剂可以降低反应温度，缩短反应时间。水解液加热至80~90℃，加入0.5%～0.7%的活性炭，脱色后过滤；在90℃下将滤液浓缩4～5h，至相对密度1.24～1.28时出料；冷却至20~25℃结晶、分离得黄色肌醇粗品，滤液再进行浓缩结晶。粗品加热溶解于水，加活性炭脱色，加入氢氧化钡溶液和草酸铵溶液，沉淀除去硫酸根和钙离子；趁热过滤，滤液冷却至30℃，再结晶、分离，并用少量的乙醇洗涤。最后在80℃下干燥8h得成品。以麸皮为原料，在30℃时用1%～1.5%的盐酸浸泡麸皮4～8h，经板框压滤机过滤，滤渣经2次浸泡，滤液用石灰乳中和至Ph=7，充分搅拌10min，过滤、洗涤得植酸钙粗品；将粗品溶解于pH=1～2的盐酸溶液中，加入活性炭脱色过滤；滤液用10%的Na2CO3溶液调pH=4.5，搅拌10min，静置1～1.5h；弃上层清液，将植酸钙浆状液置于压力锅中，后续工艺同上。

211-394-0